Name: Handbook of Her2-Targeted Agents in Breast Cancer (en Inglés)
Price: 233550.00 COP
Availability: InStock
Author: Ricardo H Alvarez; Javier Cortés; Leticia Mattos-Arruda; Mary Falzon; Angelica Fasolo; Michael Gandy; Luca Gianni; Nadia Harbeck; Martine Piccart; Stefania Zambelli; Dimitrios Zardavas
ISBN: 9781907673931

portada Handbook of Her2-Targeted Agents in Breast Cancer (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Ricardo H Alvarez; Javier Cortés; Leticia Mattos-Arruda; Mary Falzon; Angelica Fasolo; Michael Gandy; Luca Gianni; Nadia Harbeck; Martine Piccart; Stefania Zambelli; Dimitrios Zardavas

Año

2014

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

ISBN13

9781907673931

N° edición

2013

Categorías

Medicina general y de familia

Handbook of Her2-Targeted Agents in Breast Cancer (en Inglés)

Ricardo H Alvarez; Javier Cortés; Leticia Mattos-Arruda; Mary Falzon; Angelica Fasolo; Michael Gandy; Luca Gianni; Nadia Harbeck; Martine Piccart; Stefania Zambelli; Dimitrios Zardavas (Autor) · Springer · Tapa Blanda

Libro Nuevo

$ 233.550

$ 424.635

Ahorras: $ 191.086

45% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 29 de Mayo y el Miércoles 12 de Junio.

Lo recibirás en cualquier lugar de Colombia entre 1 y 5 días hábiles luego del envío.

Reseña del libro "Handbook of Her2-Targeted Agents in Breast Cancer (en Inglés)"

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.